<DOC>
	<DOC>NCT02293382</DOC>
	<brief_summary>The objective is to perform a retrospective chart review to generate data to evaluate the clinical characteristics and course of disease progression of MPS IIIB.</brief_summary>
	<brief_title>A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>1. The deceased patient was diagnosed with MPS IIIB as determined by either of the following: 1. Documented deficiency of NAGLU enzyme activity. 2. Documented functionallyrelevant mutations in both alleles of the NAGLU gene. 2. Patient's parent or legal guardian provides informed consent (unless the requirement for informed consent is waived by local regulations). 3. The availability of predefined information in the patient's clinical chart: There are no exclusion criteria for this study.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MPS IIIB</keyword>
	<keyword>Mucopolysaccharodosis III</keyword>
	<keyword>Mucopolysaccharidosis type IIIB</keyword>
	<keyword>Sanfilippo Syndrome</keyword>
</DOC>